The many faces of α-synuclein: from structure and toxicity to therapeutic target

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Nature Reviews Neuroscience

• Publication date

  2012-12-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrn3406PMID 23254192PMCID PMC4295774
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Autophagy in Dementias

  2012cited by this paper
• Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice

  2012cited by this paper
• Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease.

  2012cited by this paper
• Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity

  2012cited by this paper
• Role of α‐synuclein penetration into the membrane in the mechanisms of oligomer pore formation

  2012cited by this paper
• Characterization of Semisynthetic and Naturally Nα-Acetylated α-Synuclein in Vitro and in Intact Cells

  2012cited by this paper
• Accumulation of Toxic α-Synuclein Oligomer within Endoplasmic Reticulum Occurs in α-Synucleinopathy In Vivo

  2012cited by this paper
• Mimicking Phosphorylation at Serine 87 Inhibits the Aggregation of Human α-Synuclein and Protects against Its Toxicity in a Rat Model of Parkinson's Disease

  2012cited by this paper
• α-Synuclein Inhibits Intersynaptic Vesicle Mobility and Maintains Recycling-Pool Homeostasis

  2012cited by this paper
• α-Synuclein in Central Nervous System and from Erythrocytes, Mammalian Cells, and Escherichia coli Exists Predominantly as Disordered Monomer*

  2012cited by this paper
• α-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease.

  2012cited by this paper
• Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein

  2012cited by this paper
• α-Synuclein disrupts stress signaling by inhibiting polo-like kinase Cdc5/Plk2

  2012cited by this paper
• Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons

  2012cited by this paper
• Mechanisms of Protein Oligomerization: Inhibitor of Functional Amyloids Templates α-Synuclein Fibrillation

  2012cited by this paper
• Forkhead box protein p 1 is a transcriptional repressor of immune signaling in the CNS : implications for transcriptional dysregulation in Huntington disease

  2012cited by this paper
• Heat‐shock protein 70 modulates toxic extracellular α‐synuclein oligomers and rescues trans‐synaptic toxicity

  2011cited by this paper
• Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission

  2011cited by this paper
• Pathological roles of α-synuclein in neurological disorders.

  2011cited by this paper
• In vivo demonstration that α-synuclein oligomers are toxic

  2011cited by this paper
• Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons

  2011cited by this paper
• α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

  2011cited by this paper
• A soluble α-synuclein construct forms a dynamic tetramer

  2011cited by this paper
• Explaining the Structural Plasticity of α-Synuclein

  2011cited by this paper
• Oligomeric-Induced Activity by Thienyl Pyrimidine Compounds Traps Prion Infectivity

  2011cited by this paper
• Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death.

  2011cited by this paper
• A Pathologic Cascade Leading to Synaptic Dysfunction in α-Synuclein-Induced Neurodegeneration

  2010cited by this paper
• Entacapone and Tolcapone, Two Catechol O-Methyltransferase Inhibitors, Block Fibril Formation of α-Synuclein and β-Amyloid and Protect against Amyloid-induced Toxicity*

  2010cited by this paper
• First appraisal of brain pathology owing to A30P mutant alpha‐synuclein

  2010cited by this paper
• SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease.

  2010cited by this paper
• Aβ42 Neurotoxicity Is Mediated by Ongoing Nucleated Polymerization Process Rather than by Discrete Aβ42 Species*

  2010cited by this paper
• Non‐classical exocytosis of α‐synuclein is sensitive to folding states and promoted under stress conditions

  2010cited by this paper
• Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis.

  2010cited by this paper
• Direct Transfer of α-Synuclein from Neuron to Astroglia Causes Inflammatory Responses in Synucleinopathies*

  2010cited by this paper
• The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia

  2010cited by this paper
• α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro

  2010cited by this paper
• Increased Expression of a-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis

  2010cited by this paper
• Selective Molecular Alterations in the Autophagy Pathway in Patients with Lewy Body Disease and in Models of α-Synucleinopathy

  2010cited by this paper
• Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits α-Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions

  2010cited by this paper
• Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.

  2010cited by this paper
• Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases.

  2010cited by this paper
• Cell-Produced α-Synuclein Is Secreted in a Calcium-Dependent Manner by Exosomes and Impacts Neuronal Survival

  2010cited by this paper
• Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells

  2009cited by this paper
• Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein

  2009cited by this paper
• Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease

  2009cited by this paper
• Beclin 1 Gene Transfer Activates Autophagy and Ameliorates the Neurodegenerative Pathology in α-Synuclein Models of Parkinson's and Lewy Body Diseases

  2009cited by this paper
• α-Synuclein Alters Notch-1 Expression and Neurogenesis in Mouse Embryonic Stem Cells and in the Hippocampus of Transgenic Mice

  2008cited by this paper
• Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.

  2008cited by this paper
• Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein.

  2008cited by this paper
• The phosphorylation state of Ser-129 in human α-synuclein determines neurodegeneration in a rat model of Parkinson disease

  2008cited by this paper
• Advanced glycation end products induce in vitro cross‐linking of α‐synuclein and accelerate the process of intracellular inclusion body formation

  2008cited by this paper
• Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody.

  2008cited by this paper
• Structure of membrane-bound α-synuclein from site-directed spin labeling and computational refinement

  2008cited by this paper
• N‐terminal region of α‐synuclein is essential for the fatty acid‐induced oligomerization of the molecules

  2008cited by this paper
• Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro.

  2008cited by this paper
• Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases

  2008cited by this paper
• Alpha-synuclein is localized in a subpopulation of rat brain synaptic vesicles.

  2008cited by this paper
• The Specific Monocarboxylate Transporter-1 (MCT-1) Inhibitor, AR-C117977, Induces Donor-Specific Suppression, Reducing Acute and Chronic Allograft Rejection in the Rat

  2007cited by this paper
• Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.

  2007cited by this paper
• Development of α-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson’s disease

  2007cited by this paper
• Different species of alpha-synuclein oligomers induce calcium influx and seeding.

  2007cited by this paper
• Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease.

  2007cited by this paper
• THIS ARTICLE HAS BEEN RETRACTED: Pathological biochemistry of α‐synucleinopathy

  2007cited by this paper
• The role of α-synuclein assembly and metabolism in the pathogenesis of Lewy body disease

  2007cited by this paper
• Calpain-Cleavage of α-Synuclein : Connecting Proteolytic Processing to Disease-Linked Aggregation

  2007cited by this paper
• Different Species of α-Synuclein Oligomers Induce Calcium Influx and Seeding

  2007cited by this paper
• Pathological biochemistry of alpha-synucleinopathy.

  2007cited by this paper
• Small Molecule Inhibitors of α-Synuclein Filament Assembly†

  2006cited by this paper
• Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease.

  2006cited by this paper
• Association of alpha-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR.

  2006cited by this paper
• Small molecule inhibitors of alpha-synuclein filament assembly.

  2006cited by this paper
• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop

  2006cited by this paper
• Association of α-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR.

  2006cited by this paper
• α-Synuclein Overexpression in PC12 and Chromaffin Cells Impairs Catecholamine Release by Interfering with a Late Step in Exocytosis

  2006cited by this paper
• Inhibition of Amyloid Fibril Formation by Polyphenols: Structural Similarity and Aromatic Interactions as a Common Inhibition Mechanism

  2006cited by this paper
• Combining Neuroprotective Treatment of Embryonic Nigral Donor Tissue with Mild Hypothermia of the Graft Recipient

  2005cited by this paper
• gpwac of the T4-Type Bacteriophages: Structure, Function, and Evolution of a Segmented Coiled-Coil Protein That Controls Viral Infectivity

  2005cited by this paper
• α-Synuclein Cooperates with CSPα in Preventing Neurodegeneration

  2005cited by this paper
• Alpha-synuclein binding to rab3a in multiple system atrophy.

  2005cited by this paper
• Nucleation-Dependent Polymerization Is an Essential Component of Amyloid-Mediated Neuronal Cell Death

  2005cited by this paper
• α-Synuclein binding to rab3a in multiple system atrophy

  2005cited by this paper
• Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations.

  2005cited by this paper
• Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration.

  2005cited by this paper
• Structure and Dynamics of Micelle-bound Human α-Synuclein*

  2005cited by this paper
• Direct Observation of Aβ Amyloid Fibril Growth and Inhibition

  2004cited by this paper
• Role of alpha-synuclein in presynaptic dopamine recruitment.

  2004cited by this paper
• Alpha-synuclein locus duplication as a cause of familial Parkinson's disease.

  2004cited by this paper
• Structural determinants of PLD2 inhibition by alpha-synuclein.

  2004cited by this paper
• Role of α-Synuclein in Presynaptic Dopamine Recruitment

  2004cited by this paper
• Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques

  2004cited by this paper
• The Role of alpha-synuclein assembly and metabolism in the pathogenesis of Lewy body disease.

  2004cited by this paper
• Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.

  2004cited by this paper
• Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity.

  2004cited by this paper
• Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein.

  2004cited by this paper
• Direct observation of Abeta amyloid fibril growth and inhibition.

  2004cited by this paper
• The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia

  2004cited by this paper
• Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions.

  2004cited by this paper
• α-synuclein locus duplication as a cause of familial Parkinson's disease

  2004cited by this paper
• Hsp70 Reduces α-Synuclein Aggregation and Toxicity*

  2004cited by this paper
• Demonstration of a role for α-synuclein as a functional microtubule-associated protein

  2004cited by this paper

• CPEB3 selectively inhibits α-synuclein aggregation without modulating TDP-43 pathology.

  2026cites this paper
• A Degron Decoy System Co-opts Pathological Seeding to Enable Clearance of Multimeric α-Synuclein

  2026cites this paper
• Emphasizing the role of oxidative stress and Sirt-1/Nrf2 and TLR-4/NF-κB in Tamarix aphylla mediated neuroprotective potential in rotenone-induced Parkinson’s disease: In silico and in vivo study

  2026cites this paper
• Treatment of Parkinson’s Disease with Traditional Chinese Medicine and Western Medicine

  2026cites this paper
• Non-invasive CRISPR/Cas9 nanocapsules specifically edit α-synuclein for effective Parkinson’s disease treatment

  2026cites this paper
• Ultrasensitive Detection of Alpha-Synuclein Oligomers in Human Plasma Using Optimized Nano-QuIC

  2026cites this paper
• Structural analysis of the asymmetric interaction between amyloid β42 and α-Synuclein: Amyloid β42 oligomers promote α-synuclein aggregation while α-synuclein inhibits amyloid β42 aggregation.

  2026cites this paper
• Phytomicronutrients in neurodegeneration: modulating microglial dynamics for neuroprotection

  2026cites this paper
• A commercial insecticide-induced neurotoxicity and snake venom nerve growth factor-inspired peptides-mediated neuroprotection in Caenorhabditis elegans: Mechanistic, safety, and pharmacokinetic (in vivo imaging) evaluation of peptides.

  2026cites this paper
• Zinc-α₂-glycoprotein overexpression attenuates gasdermin D-mediated pyroptosis in dopaminergic neurons by suppressing reactive oxygen species/mitogen-activated protein kinase signaling.

  2026cites this paper
• Diagnostics of Synucleinopathies by Protein Amplification Methods: Methodological and Bibliometric Analysis

  2026cites this paper
• Unlocking the potential of lipid-based nanoparticles for intranasal drug delivery in Parkinson's disease.

  2026cites this paper
• Micro-nanoplastics and Parkinson’s disease: evidence and perspectives

  2026cites this paper
• Targeting the alpha-synuclein protein to treat Parkinson's disease using novel inhibitors identified using an integrated computational drug development approaches

  2025cites this paper
• Beyond Pathology: α-Synuclein Homeostasis and Three Principles to Guide Research.

  2025cites this paper
• Pathological Folding of α-Synuclein on Polystyrene Nanoplastic Revealed by Sum Frequency Scattering and 2D Infrared Spectroscopy.

  2025cites this paper
• Unraveling synucleinopathies: Recent breakthroughs in Parkinson's disease therapy.

  2025cites this paper
• Theoretical Methods for Assessing the Density of Protein Nanodroplets

  2025cites this paper
• Spectral Profiling of Early αsyn Aggregation in HEK293 Cells Modified to Stably Express Human WT and A53T-αsyn

  2025cites this paper
• Inhibition or genetic reduction of ASAH1/acid ceramidase restore α-synuclein clearance in mutant GBA1 dopamine neurons from Parkinson’s patients

  2025cites this paper
• Meta-analysis and in-silico functional characterization of the SNCA variant rs356220 in Parkinson’s disease

  2025cites this paper
• Marqueurs biologiques des maladies neurodégénératives

  2025cites this paper
• Comprehensive analysis of regulated cell death pathways: intrinsic disorder, protein–protein interactions, and cross-pathway communication

  2025cites this paper
• Concentration-Dependent Mutational Scanning Probes the Cellular Folding Landscape of α-Synuclein in Yeast

  2025cites this paper
• The Aggregation Continuum of α-Synuclein and Its Relevance to Brain Aging.

  2025cites this paper
• Identification of small molecule dimethyoxyphenyl piperazine inhibitors of alpha-synuclein fibril growth

  2025cites this paper
• A critical review on neurodegenerative biomarker diagnostics: where is the field heading to?

  2025cites this paper
• Protein Recognition of Linear and Cyclic Peptides of Homologous Sequences Implicated in the Aggregation of α‑Synuclein

  2025cites this paper
• NATO3 protects dopaminergic neurons in mouse in vivo and human in vitro Parkinson’s disease models

  2025cites this paper
• MPP+ induces α-synuclein oligomerization and neurite impairment by disrupting mitochondrial function and Akt signaling, with apigenin emerging as a potential neuroprotective agent.

  2025cites this paper
• Complementary Structural and Chemical Biology Methods Reveal the Basis for Selective Radioligand Binding to α-Synuclein in MSA Tissue

  2025cites this paper
• Inhibition of α-synuclein aggregation by MCC950 attenuates dopaminergic neuronal damage in MN9D cells.

  2025cites this paper
• Therapeutic applications of exercise in neurodegenerative diseases: focusing on the mechanism of SIRT1

  2025cites this paper
• Molecular mechanisms of exercise-induced neuroprotection against Parkinson's disease.

  2025cites this paper
• The Yeast Parkinson’s Disease Model Exhibits An Increase in Peroxisome Number Independent of the Division Proteins Vps1 and Dnm1

  2025cites this paper
• Multivalent interaction induces phase separation and formation of more toxic aggregates of α-syn in a yeast model of Parkinson’s disease

  2025cites this paper
• Current Perspectives on Pathogenesis, Clinical Manifestations, and Treatment of Parkinson's Disease

  2025cites this paper
• Delineating the Mechanistic Insight of Inhibition of α-Synuclein Fibrillation by Neuro Metabolite, Myo-inositol: Implications in Synucleopathies-Related Disorders.

  2025cites this paper
• Increased burden of rare risk variants across gene expression networks predisposes to sporadic Parkinson’s disease

  2025cites this paper
• Transformative progress in Raman optical activity: recent advances and innovations

  2025cites this paper
• The gut–brain axis in early Parkinson’s disease: from prodrome to prevention

  2025cites this paper
• Lipid metabolism in health and disease: Mechanistic and therapeutic insights for Parkinson’s disease

  2025cites this paper
• α‐Synuclein Sequences from Long‐Lived Animals Display Generally Diminished Aggregation Compared to Shorter‐Lived Animals Including Humans

  2025cites this paper
• Repurposing the memory-promoting meclofenoxate hydrochloride as a treatment for Parkinson’s disease through integrative multi-omics analysis

  2025cites this paper
• Formation of seeding-competent α-synuclein aggregates in parkin-deficient iPSC-derived human neurons

  2025cites this paper
• Identification of Small Molecule Dimethyoxyphenyl Piperazine Inhibitors of Alpha-Synuclein Fibril Growth

  2025cites this paper
• Elevated plasma levels of alpha-synuclein are dispensable for Parkinson’s disease pathology

  2025cites this paper
• Hypoxia ameliorates neurodegeneration and movement disorder in a mouse model of Parkinson’s disease

  2025cites this paper
• Decoding physical environment's role in protein phase transition.

  2025cites this paper
• Targeting phagocytosis for amyloid-β clearance: implications of morphology remodeling and microglia activation probed by bifunctional chimaeras

  2025cites this paper
• Research progress on natural products in regulating the gut microbiota in Parkinson’s disease

  2025cites this paper
• Natural Products from Chinese Medicine Targeting NF-κB Signaling: Emerging Therapeutic Avenues for Neurodegenerative Diseases

  2025cites this paper
• A Review of the Recent Advances in the Pharmacological Management of Parkinson’s Disease

  2025cites this paper
• Lactiplantibacillus plantarum as a Psychobiotic Strategy Targeting Parkinson’s Disease: A Review and Mechanistic Insights

  2025cites this paper
• R406 and its structural analogs reduce SNCA/α-synuclein levels via autophagic degradation

  2025cites this paper
• Temporin-1CEa and its Analog LK2(6)A(L) Confer Neuroprotective Effects in Parkinson’s Disease Model by Attenuating Neuroinflammation Via the NF-κB and MAPK Signaling Pathways

  2025cites this paper
• Rising Stars: Molecular Mechanisms and Chemical Interventions of α-Synuclein Amyloid Aggregation in Parkinson's Disease.

  2025cites this paper
• Marcatori biologici delle malattie neurodegenerative

  2025cites this paper
• Olive polyphenols as modulators of amyloid aggregation: mechanisms and implications for neurodegenerative diseases.

  2025cites this paper
• Targeted α-Synuclein mRNA Degradation by PMO-Based RNA-Degrading Chimeras

  2025cites this paper
• Sequencing of α-synuclein Intrinsically Disordered Protein in MoS2 Nanopores

  2025cites this paper
• Etiopathogenesis, Clinical Manifestations, and Management of Parkinson's Disease

  2025cites this paper
• Modulation of α-Synuclein Fibrillation and Toxicity by 4-Phenylbutyric Acid

  2025cites this paper
• Salt-Induced Membrane-Bound Conformation of the NAC Domain of α-Synuclein Leads to Structural Polymorphism of Amyloid Fibrils

  2025cites this paper
• Effectiveness of mesenchymal stem cell-derived extracellular vesicles therapy for Parkinson’s disease: A systematic review of preclinical studies

  2025cites this paper
• Outlook of SNCA (α-synuclein) transgenic fly models in delineating the sequel of mitochondrial dysfunction in Parkinson's disease.

  2025cites this paper
• Listerin promotes α-synuclein degradation to alleviate Parkinson’s disease through the ESCRT pathway

  2025cites this paper
• Efficacy of transcranial direct current stimulation on cognitive function in patients with Parkinson's disease: a systematic review and meta-analysis

  2025cites this paper
• Kinetics of Amyloid Oligomer Formation.

  2025cites this paper
• Enhancing sleep quality in synucleinopathies through physical exercise

  2025cites this paper
• Targeted Raman Visualization and Mitigation of α-Synuclein Amyloidogenesis in Living Zebrafish by a Nanobody-Decorated Polydiacetylene.

  2025cites this paper
• Current amyloid inhibitors: therapeutic applications and nanomaterial-based innovations.

  2025cites this paper
• A personalised and comprehensive approach is required to suppress or replenish SNCA for Parkinson’s disease

  2025cites this paper
• SNAP-25: A biomarker of synaptic loss in neurodegeneration.

  2025cites this paper
• Imaging probes for the detection of brain microenvironment.

  2025cites this paper
• The neurotoxicity of pesticides: Implications for Parkinson's disease.

  2025cites this paper
• Gut microbiota and Parkinson’s Disease: a new frontier in understanding neurological health

  2025cites this paper
• Neural-induced human adipose tissue-derived stem cell secretome exerts neuroprotection against rotenone-induced Parkinson’s disease in rats

  2025cites this paper
• Alpha-synuclein pathology and Parkinson’s disease-related olfactory dysfunctions: an update on preclinical models and therapeutic approaches

  2025cites this paper
• Monomers, Dimers, and Oligomers of Pyroglutamate-Modified α‑Synuclein Fragments Exhibit Distinct Biophysical Characteristics

  2025cites this paper
• Effect of RNA on the supramolecular architecture of α-synuclein fibrils

  2025cites this paper
• Neuroprotective Effect of an Unsaturated Mannuronate Oligosaccharide Derived from Enzyme-degraded Polymannuronate on an In Vitro Parkinson’s Disease-like Model

  2025cites this paper
• MEK1/2 inhibitors suppress pathological α-synuclein and neurotoxicity in cell models and a humanized mouse model of Parkinson's disease.

  2025cites this paper
• Approaching α-synuclein misfolding through gut microbiome; strategies for the management of neurological conditions

  2025cites this paper
• In vivo validation of novel non-invasive PHP.eB AAVs as a potential therapeutic approach for alpha-synucleinopathies

  2025cites this paper
• Anion Binding and Aggregation of N‑Terminal α‑Synuclein Peptides

  2025cites this paper
• Combining light-induced aggregation and biotin proximity labeling implicates endolysosomal proteins in early α-synuclein oligomerization

  2025cites this paper
• Glycated alpha-synuclein assemblies cause distinct Parkinson’s disease pathogenesis in mice

  2025cites this paper
• Emerging Techniques for the Identification of Traditional Chinese Medicine-Derived Molecules Targeting Parkinson's Disease.

  2025cites this paper
• Clearance Pathways for α‐Synuclein in Parkinson's Disease

  2025cites this paper
• Bioanalytical Considerations for Biomarkers of Parkinson's Disease

  2025cites this paper
• C-Terminal Radical Oxidation Inhibits α-Synuclein Aggregation and Cytotoxicity via an Oxidative Oligomer-Disrupting Pathway.

  2025cites this paper
• Development of Positron Emission Tomography Radiotracers for Imaging α-Synuclein Aggregates

  2025cites this paper
• Oxidation-induced destabilization of polymorphic α-synuclein fibrils: insights from molecular dynamics

  2025cites this paper
• Distinct CSF α-synuclein aggregation profiles associated with Alzheimer's disease phenotypes and MCI-to-AD conversion

  2025cites this paper
• The physiological and pathological effects of sphingolipid metabolism and signaling in the central nervous system

  2025cites this paper
• Alpha-Synuclein Dysregulation in Systemic Pathophysiology of Synucleinopathies.

  2025influential citation
• Physical and Mechanical Properties of Monomeric Alpha-Synuclein Provide Leads to Molecular Function

  2025cites this paper
• Acupuncture modulates the microbiota-gut-brain axis: a new strategy for Parkinson’s disease treatment

  2025cites this paper
• α-Synuclein orchestrates Th17 responses as antigen and adjuvant in Parkinson’s disease

  2025cites this paper